Adenocarcinoma, Clear Cell
Welcome,         Profile    Billing    Logout  
 10 Companies   20 Products   20 Products   34 Mechanisms of Action   0 Trials   52 News 


12»
  • ||||||||||  dalantercept (ACE-041) / Merck (MSD)
    Trial completion, Trial primary completion date:  Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) -  May 31, 2017   
    P2,  N=28, Completed, 
    Phase classification: P=N/A --> P | Phase classification: PN/A --> P1 Active, not recruiting --> Completed | Trial primary completion date: Nov 2013 --> Jan 2016
  • ||||||||||  trebananib (AMG 386) / Amgen
    Trial completion, Enrollment change, Trial primary completion date:  Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer (clinicaltrials.gov) -  May 4, 2017   
    P2,  N=35, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Nov 2013 --> Jan 2016 Active, not recruiting --> Completed | N=55 --> 35 | Trial primary completion date: Mar 2016 --> Jul 2016
  • ||||||||||  carboplatin / Generic mfg., paclitaxel / Generic mfg., dasatinib / Generic mfg.
    Enrollment closed, Metastases:  Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (clinicaltrials.gov) -  Jul 14, 2015   
    P=N/A,  N=15, Active, not recruiting, 
    N=15 --> 18 | Trial primary completion date: Dec 2015 --> Jul 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Dec 2015 | Recruiting --> Active, not recruiting
  • ||||||||||  nintedanib / Generic mfg.
    Enrollment closed, Enrollment change, Trial primary completion date:  Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) -  Dec 25, 2014   
    P2,  N=36, Active, not recruiting, 
    Active, not recruiting --> Completed Suspended --> Active, not recruiting | N=55 --> 36 | Trial primary completion date: Nov 2014 --> Nov 2015
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion, Trial primary completion date, Metastases:  High-dose Bevacizumab in Advanced Renal Carcinoma Patients (clinicaltrials.gov) -  Dec 22, 2014   
    P2,  N=119, Completed, 
    Suspended --> Active, not recruiting | N=55 --> 36 | Trial primary completion date: Nov 2014 --> Nov 2015 Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Jul 2013
  • ||||||||||  Trial completion, Gene therapy:  Gene Therapy in Treating Patients With Cancer (clinicaltrials.gov) -  Feb 19, 2014   
    P1,  N=0, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Sutent (sunitinib) / Pfizer
    New P2 trial:  Sunitinib (clinicaltrials.gov) -  Apr 3, 2013   
    P2,  N=30, Recruiting,